CY1121701T1 - Οργανικες ενωσεις μονοβακταμης για την αντιμετωπιση βακτηριακων λοιμωξεων - Google Patents
Οργανικες ενωσεις μονοβακταμης για την αντιμετωπιση βακτηριακων λοιμωξεωνInfo
- Publication number
- CY1121701T1 CY1121701T1 CY20191100371T CY191100371T CY1121701T1 CY 1121701 T1 CY1121701 T1 CY 1121701T1 CY 20191100371 T CY20191100371 T CY 20191100371T CY 191100371 T CY191100371 T CY 191100371T CY 1121701 T1 CY1121701 T1 CY 1121701T1
- Authority
- CY
- Cyprus
- Prior art keywords
- organic
- treatment
- bacterial infections
- compounds
- monobactam compounds
- Prior art date
Links
- 208000035143 Bacterial infection Diseases 0.000 title 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical class O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 title 1
- 208000022362 bacterial infectious disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461969735P | 2014-03-24 | 2014-03-24 | |
| US201462088304P | 2014-12-05 | 2014-12-05 | |
| PCT/US2015/022011 WO2015148379A1 (en) | 2014-03-24 | 2015-03-23 | Monobactam organic compounds for the treatment of bacterial infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121701T1 true CY1121701T1 (el) | 2020-07-31 |
Family
ID=52808201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100371T CY1121701T1 (el) | 2014-03-24 | 2019-04-03 | Οργανικες ενωσεις μονοβακταμης για την αντιμετωπιση βακτηριακων λοιμωξεων |
Country Status (37)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202092620A1 (ru) * | 2015-09-23 | 2021-06-30 | Новартис Аг | Соли и твердые формы монобактамного антибиотика |
| WO2017081615A1 (en) | 2015-11-09 | 2017-05-18 | Wockhardt Limited | 7-oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections |
| CA3008006C (en) | 2015-12-15 | 2024-04-09 | Merck Sharp & Dohme Corp. | Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections |
| KR102408800B1 (ko) | 2016-03-07 | 2022-06-13 | 머크 샤프 앤드 돔 코포레이션 | 비시클릭 아릴 모노박탐 화합물 및 박테리아 감염의 치료를 위한 그의 사용 방법 |
| ES2966369T3 (es) | 2017-03-20 | 2024-04-22 | Broad Inst Inc | Compuestos y métodos para el tratamiento de enfermedades parasitarias |
| CN111094281B (zh) * | 2017-08-02 | 2023-08-29 | 诺华股份有限公司 | 用于制备单内酰胺抗生素的化学方法及其中间体 |
| WO2019058346A1 (en) * | 2017-09-22 | 2019-03-28 | Novartis Ag | MONOBACTAM ADMINISTRATION IN ASSOCIATION WITH ANTIBIOTIC AGENT FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION |
| SG11202002575UA (en) | 2017-10-02 | 2020-04-29 | Merck Sharp & Dohme | Chromane monobactam compounds for the treatment of bacterial infections |
| SG11202002300QA (en) * | 2017-10-02 | 2020-04-29 | Arixa Pharmaceuticals Inc | Aztreonam derivatives and uses thereof |
| WO2019092180A1 (en) * | 2017-11-10 | 2019-05-16 | Novartis Ag | Administration of monobactam for the treatment of urinary tract infection |
| US11459323B2 (en) | 2018-01-29 | 2022-10-04 | Medshine Discovery Inc. | Monocyclic β-lactam compound for treating bacterial infection |
| KR102017784B1 (ko) * | 2018-04-11 | 2019-09-03 | 전북대학교산학협력단 | 민감성 및 선택성을 개선한 캠필로박터 검출용 배지 조성물 및 이를 이용한 캠필로박터 검출방법 |
| KR102017785B1 (ko) * | 2018-05-17 | 2019-09-03 | 전북대학교산학협력단 | 민감성 및 선택성을 개선한 캠필로박터 선택증균용 배지 조성물 및 이를 이용한 캠필로박터 검출방법 |
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| IL280770B2 (en) | 2018-08-09 | 2024-05-01 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| TW202024068A (zh) | 2018-11-13 | 2020-07-01 | 大陸商南京聖和藥業股份有限公司 | 單環內醯胺化合物及其應用 |
| JP7179185B2 (ja) * | 2018-12-18 | 2022-11-28 | メッドシャイン ディスカバリー インコーポレイテッド | 医薬の製造おける単環式β－ラクタム化合物の使用 |
| KR102786898B1 (ko) * | 2019-11-22 | 2025-03-25 | 쑤저우 얼예 파마슈티칼 컴퍼니 리미티드 | 설포닐우레아 고리 치환 모노시클릭 β-락탐계 항생제 |
| CN111303144B (zh) * | 2019-12-13 | 2020-11-27 | 苏州信诺维医药科技有限公司 | 一种治疗细菌感染的化合物 |
| US12491180B2 (en) | 2019-12-19 | 2025-12-09 | Shenzhen Optimum Biological Technology Co., Ltd | Application of compound in treating pneumonia |
| EP3838266A1 (en) | 2019-12-20 | 2021-06-23 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Microfluidic production of biofunctionalized giant unilamellar vesicles for targeted intracellular cargo delivery |
| CN113754651B (zh) * | 2020-06-02 | 2023-04-18 | 中国医学科学院医药生物技术研究所 | 一种β-内酰胺化合物、其用途及其制备方法 |
| EP4165039B1 (en) * | 2020-07-16 | 2024-08-21 | Ningxia Academy of Agriculture and Forestry Sciences | Novel monobactam compounds, their preparation and use as antibacterial agents |
| WO2022185240A1 (en) | 2021-03-04 | 2022-09-09 | Bp Asset Vi, Inc. | Formulation of a monobactam antibiotic |
| WO2022185241A1 (en) | 2021-03-04 | 2022-09-09 | Bp Asset Vi, Inc. | Process for manufacturing a monobactam antibiotic |
| KR20240105442A (ko) | 2021-11-18 | 2024-07-05 | 머크 샤프 앤드 돔 엘엘씨 | 크로만 아미딘 모노박탐 항생제 |
| CN115304594B (zh) | 2022-10-12 | 2023-02-14 | 苏州二叶制药有限公司 | 磺酰脲环取代的化合物的盐型及其晶型 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ196202A (en) | 1980-02-07 | 1984-07-31 | Squibb & Sons Inc | Beta-lactam antibiotics (of azetidine-sulphonic acid type) |
| US4775670A (en) | 1980-09-29 | 1988-10-04 | E. R. Squibb & Sons, Inc. | 2-oxo-1-azetidinesulfonic acid salts |
| EP0048953B1 (en) | 1980-09-29 | 1988-03-09 | E.R. Squibb & Sons, Inc. | Beta-lactam antibiotics |
| WO1982001873A1 (en) * | 1980-12-05 | 1982-06-10 | Takeda Chemical Industries Ltd | 1-sulfo-2-oxoazetidine derivatives and process for their preparation |
| JPS58210061A (ja) * | 1982-05-31 | 1983-12-07 | Takeda Chem Ind Ltd | １−スルホ−２−オキソアゼチジン誘導体、その製造法および用途 |
| US4782147A (en) * | 1980-12-05 | 1988-11-01 | Takeda Chemical Industries, Ltd. | 1-sulfo-2-oxoazetidine derivatives and their production |
| JPS58189176A (ja) * | 1982-04-30 | 1983-11-04 | Takeda Chem Ind Ltd | １−スルホ−２−アゼチジノン誘導体およびその製造法 |
| CA1262128A (en) | 1981-08-27 | 1989-10-03 | Christian N. Hubschwerlen | .beta.-lactams |
| IL67451A (en) | 1981-12-25 | 1987-10-20 | Takeda Chemical Industries Ltd | 4-cyano-2-azetidinones and production thereof and process for the preparation of 4-carbamoyl-2-azetidinones using them |
| GB2116183B (en) | 1982-03-03 | 1985-06-05 | Genentech Inc | Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it |
| AU564150B2 (en) * | 1982-04-30 | 1987-08-06 | Takeda Chemical Industries Ltd. | 1-sulfo-2-azetidinone derivatives |
| HU189290B (en) | 1982-05-31 | 1986-06-30 | Banyu Pharmaceutical Co Ltd,Jp | Process for preparing new 2-oxo-1-azetidine-sulphonic acid derivatives and pharmaceutically acceptable salts thereof, further pharmaceutical compositions containing such derivatives as active substances |
| EP0096297B1 (de) | 1982-06-03 | 1988-06-15 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Verfahren zur Herstellung von 1-Sulfo-2-oxoazetidinderivaten |
| JPS6153282A (ja) | 1984-08-22 | 1986-03-17 | Banyu Pharmaceut Co Ltd | 単環β−ラクタム誘導体 |
| JPS6153283A (ja) | 1984-08-24 | 1986-03-17 | Banyu Pharmaceut Co Ltd | ２−オキソ−１−アゼチジンスルホン酸誘導体 |
| US4610824A (en) | 1984-10-09 | 1986-09-09 | E. R. Squibb & Sons, Inc. | Hydrazide derivatives of monocyclic beta-lactam antibiotics |
| US5112968A (en) | 1989-07-28 | 1992-05-12 | E. R. Squibb & Sons, Inc. | Monobactam hydrazide derivatives |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| DE69738749D1 (de) | 1996-08-16 | 2008-07-17 | Schering Corp | Zelloberflächen-antigen aus säugetieren und verwandte reagenzien |
| JP2001520039A (ja) | 1997-10-21 | 2001-10-30 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ヒト腫瘍壊死因子レセプター様タンパク質、ｔｒ１１，ｔｒ１１ｓｖ１およびｔｒ１１ｓｖ２ |
| WO1999040196A1 (en) | 1998-02-09 | 1999-08-12 | Genentech, Inc. | Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same |
| ES2295040T3 (es) | 1999-07-12 | 2008-04-16 | Genentech, Inc. | Promocion o inhibicion de la angiogenesis y cardiovascularizacion mediante homologos del ligando / receptor del factor de necrosis del tumor. |
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| US7618632B2 (en) | 2003-05-23 | 2009-11-17 | Wyeth | Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies |
| EP1660126A1 (en) | 2003-07-11 | 2006-05-31 | Schering Corporation | Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer |
| WO2005055808A2 (en) | 2003-12-02 | 2005-06-23 | Genzyme Corporation | Compositions and methods to diagnose and treat lung cancer |
| GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| EP1765402A2 (en) | 2004-06-04 | 2007-03-28 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
| CA2602777C (en) | 2005-03-25 | 2018-12-11 | Tolerrx, Inc. | Gitr binding molecules and uses therefor |
| EP2439273B1 (en) | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US20110212086A1 (en) | 2006-01-19 | 2011-09-01 | Genzyme Corporation | GITR Antibodies For The Treatment of Cancer |
| EP2069347A2 (en) | 2006-09-27 | 2009-06-17 | Merck & Co., Inc. | Novel inhibitors of beta-lactamase |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| DK2175884T3 (en) | 2007-07-12 | 2016-09-26 | Gitr Inc | Combination USING GITR BINDING MOLECULES |
| DK2231667T3 (da) | 2008-01-18 | 2013-12-16 | Merck Sharp & Dohme | Beta-lactamase-hæmmere |
| RU2531758C2 (ru) | 2008-02-11 | 2014-10-27 | Куретек Лтд. | Моноклональные антитела для лечения опухолей |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| US20110177070A1 (en) | 2008-07-02 | 2011-07-21 | Emergent Product Development Seatlle, LLC | TGF-Beta Antagonist Multi-Target Binding Proteins |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| MX2011002250A (es) | 2008-08-25 | 2011-08-17 | Amplimmune Inc | Antagonistas de muerte celular programada-1 y métodos de uso de los mismos. |
| RS54233B1 (sr) | 2008-08-25 | 2015-12-31 | Amplimmune Inc. | Kompozicije pd-1 antagonista i postupci za njihovu primenu |
| US8586023B2 (en) | 2008-09-12 | 2013-11-19 | Mie University | Cell capable of expressing exogenous GITR ligand |
| KR101655961B1 (ko) | 2008-10-31 | 2016-09-08 | 시오노기세야쿠 가부시키가이샤 | 카테콜기를 갖는 세팔로스포린류 |
| US8217149B2 (en) | 2008-12-09 | 2012-07-10 | Genentech, Inc. | Anti-PD-L1 antibodies, compositions and articles of manufacture |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| US20120053350A1 (en) | 2009-04-30 | 2012-03-01 | Ian Mangion | Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids |
| SG178991A1 (en) | 2009-09-03 | 2012-04-27 | Schering Corp | Anti-gitr antibodies |
| GB0919054D0 (en) | 2009-10-30 | 2009-12-16 | Isis Innovation | Treatment of obesity |
| WO2011061760A1 (en) | 2009-11-18 | 2011-05-26 | Cadila Healthcare Limited | Novel antithrombotic agents |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| PT2519543T (pt) | 2009-12-29 | 2016-10-07 | Emergent Product Dev Seattle | Proteínas de ligação de heterodímero e suas utilizações |
| JP2012027846A (ja) | 2010-07-27 | 2012-02-09 | Sony Corp | 情報処理装置、情報表示方法及びコンピュータプログラム |
| DK2646436T3 (en) | 2010-11-29 | 2015-06-29 | Pfizer | monobactams |
| PL2748151T3 (pl) | 2011-08-25 | 2016-09-30 | Pirymidynowe inhibitory pde10 | |
| EP3052497B1 (en) | 2011-09-13 | 2017-06-28 | Wockhardt Limited | Nitrogen containing compounds and their use |
| WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
| LT2785375T (lt) | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antikūnai ir jų panaudojimas |
| US8796257B2 (en) | 2011-12-02 | 2014-08-05 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors |
| UY34585A (es) | 2012-01-24 | 2013-09-02 | Aicuris Gmbh & Co Kg | Compuestos b-lactámicos sustituidos con amidina, su preparación y uso |
| EP2814483A2 (en) | 2012-02-15 | 2014-12-24 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| AU2013237939A1 (en) | 2012-03-30 | 2014-10-30 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors |
| MX2014011825A (es) | 2012-03-30 | 2015-02-20 | Cubist Pharm Inc | INHIBIDORES DE ISOXAZOL ß-LACTAMASA. |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| AU2013308127B2 (en) | 2012-08-25 | 2015-08-13 | Wockhardt Limited | 1,6- Diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections |
| CN103044416A (zh) | 2012-12-17 | 2013-04-17 | 浙江华方药业有限责任公司 | 一种卡芦莫南钠的合成方法 |
| WO2014141132A1 (en) | 2013-03-14 | 2014-09-18 | Naeja Pharmaceutical Inc. | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
| US20160326157A1 (en) | 2014-01-06 | 2016-11-10 | President And Fellows Of Harvard College | Monobactams and methods of their synthesis and use |
-
2015
- 2015-03-23 WO PCT/US2015/022011 patent/WO2015148379A1/en not_active Ceased
- 2015-03-23 HR HRP20190501TT patent/HRP20190501T1/hr unknown
- 2015-03-23 PE PE2016001601A patent/PE20161371A1/es unknown
- 2015-03-23 AU AU2015236369A patent/AU2015236369B2/en active Active
- 2015-03-23 HU HUE15714147A patent/HUE042134T2/hu unknown
- 2015-03-23 UA UAA201608977A patent/UA121383C2/uk unknown
- 2015-03-23 CU CU2016000131A patent/CU24441B1/es unknown
- 2015-03-23 CA CA2939254A patent/CA2939254C/en active Active
- 2015-03-23 SI SI201530680T patent/SI3122745T1/sl unknown
- 2015-03-23 PL PL15714147T patent/PL3122745T3/pl unknown
- 2015-03-23 PT PT15714147T patent/PT3122745T/pt unknown
- 2015-03-23 KR KR1020167024716A patent/KR101733441B1/ko active Active
- 2015-03-23 MX MX2016011822A patent/MX373444B/es active IP Right Grant
- 2015-03-23 ES ES18215940T patent/ES2862203T3/es active Active
- 2015-03-23 LT LTEP15714147.4T patent/LT3122745T/lt unknown
- 2015-03-23 EP EP18215940.0A patent/EP3511328B1/en active Active
- 2015-03-23 JP JP2016558569A patent/JP6153674B2/ja active Active
- 2015-03-23 EP EP15714147.4A patent/EP3122745B1/en active Active
- 2015-03-23 US US14/665,245 patent/US9174978B2/en active Active
- 2015-03-23 AP AP2016009374A patent/AP2016009374A0/en unknown
- 2015-03-23 MY MYPI2016702871A patent/MY179292A/en unknown
- 2015-03-23 SM SM20190218T patent/SMT201900218T1/it unknown
- 2015-03-23 BR BR112016020333-0A patent/BR112016020333B1/pt active IP Right Grant
- 2015-03-23 TW TW104109243A patent/TWI714525B/zh active
- 2015-03-23 SG SG11201606711UA patent/SG11201606711UA/en unknown
- 2015-03-23 MA MA39777A patent/MA39777B1/fr unknown
- 2015-03-23 DK DK15714147.4T patent/DK3122745T3/en active
- 2015-03-23 ES ES15714147T patent/ES2719136T3/es active Active
- 2015-03-23 DK DK18215940.0T patent/DK3511328T3/da active
- 2015-03-23 EA EA201691766A patent/EA030850B1/ru not_active IP Right Cessation
- 2015-03-23 CN CN201580015867.7A patent/CN106164072B/zh active Active
- 2015-03-23 PH PH1/2016/501577A patent/PH12016501577B1/en unknown
- 2015-03-23 RS RS20190406A patent/RS58509B1/sr unknown
- 2015-09-22 US US14/861,797 patent/US10369138B2/en active Active
-
2016
- 2016-08-11 ZA ZA2016/05565A patent/ZA201605565B/en unknown
- 2016-08-14 IL IL247259A patent/IL247259B/en active IP Right Grant
- 2016-09-09 CL CL2016002285A patent/CL2016002285A1/es unknown
- 2016-09-12 SV SV2016005274A patent/SV2016005274A/es unknown
- 2016-09-12 EC ECIEPI201673620A patent/ECSP16073620A/es unknown
- 2016-09-12 GT GT201600183A patent/GT201600183A/es unknown
-
2019
- 2019-04-03 CY CY20191100371T patent/CY1121701T1/el unknown
- 2019-04-10 US US16/380,243 patent/US20190231752A1/en not_active Abandoned
-
2020
- 2020-03-19 US US16/823,485 patent/US20200276169A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121701T1 (el) | Οργανικες ενωσεις μονοβακταμης για την αντιμετωπιση βακτηριακων λοιμωξεων | |
| CY1122305T1 (el) | Ενωσεις υδροξαζολης υδροξαμικου οξεος ως αναστολεις lpxc | |
| CY1122805T1 (el) | Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων | |
| PH12016502436A1 (en) | Anti-infective compounds | |
| CY1121384T1 (el) | Συνδυαστικη θεραπεια για την αγωγη ανθεκτικων βακτηριακων λοιμωξεων | |
| EA201691534A1 (ru) | Лечение устойчивых угрей | |
| NZ724798A (en) | Polymyxin derivatives as antimicrobial compounds | |
| PH12016501988A1 (en) | Antibacterial compounds | |
| CL2020001147A1 (es) | Compuestos antibacterianos | |
| MX389771B (es) | Compuestos de minociclina para biodefensas. | |
| MX376475B (es) | Derivado de polimixina y usos del mismo. | |
| MX2019011908A (es) | Macrociclos de peptidos anti-bacterianos y uso de los mismos. | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
| CL2017001276A1 (es) | Derivados de benzotiazol antibacterianos | |
| PH12016501532A1 (en) | Antibacterial combinations comprising polymyxin | |
| MX380076B (es) | Inhibidores de beta-lactamasa. | |
| MX373098B (es) | Derivados de manosa para tratar infecciones bacterianas. | |
| JO3477B1 (ar) | مركبات أحادي باكتام عضوية لعلاج العدوى البكتيرية | |
| CY1119316T1 (el) | Υδροχλωρικα αλατα μιας αντιβιοτικης ενωσης | |
| BR112017022796A2 (pt) | composições antibacterianas e métodos | |
| CR20160412A (es) | Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas | |
| TH171934A (th) | สารประกอบอินทรีย์มอนอแบคแทมสำหรับการรักษาการติดเชื้อแบคทีเรีย | |
| TH104715B (th) | สารประกอบและวิธีการสำหรับการรักษาการติดเชื้อแบคทีเรีย |